HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical Efficacy of Crizotinib in Advanced ALK Positive 
Non-small Cell Lung Cancer].

AbstractBACKGROUND:
The aim of this study is to explore clinical efficacy of crizotinib in advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer.
METHODS:
patients with advanced non-small cell lung cancer habouring ALK positive were randomly divided into crizotinib group (n=14) and chemotherapy group (n=14). Patients in the crizotinib group were receive oral treatment with crizotinib (250 mg) twice daily. Patients in the chemotherapy group were administrated docetaxel injection (75 mg/m2) every three weeks and every patient was treated at least 3 period. Then clinical efficacy was observed after 12 mo followed-up.
RESULTS:
Effective rate of patients in the crizotinib group was 64.29%. It was significantly higher than that of the chemotherapy group (21.43%)(P=0.026). The stable rate of patients in the crizotinib group was 85.71%. It was significantly higher than that of the chemotherapy group 40.86% (χ2=5.600, P=0.018). Median progression free survival (PFS) of the crizotinib group was 7.0 mo. It was longer than that of the chemotherapy group (4.0 mo)(P=0.002).
CONCLUSIONS:
Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced ALK positive non-small cell lung cancer. The median PFS of patients is shorter. It can improve the quality of life about patients.
.
AuthorsJing Zhao, Kun Zhang, Liyu Zhang, Hong Wang
JournalZhongguo fei ai za zhi = Chinese journal of lung cancer (Zhongguo Fei Ai Za Zhi) Vol. 18 Issue 10 Pg. 616-20 (Oct 20 2015) ISSN: 1999-6187 [Electronic] China
PMID26483333 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases
Topics
  • Adult
  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents (administration & dosage, adverse effects)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, enzymology, genetics)
  • Crizotinib
  • Female
  • Humans
  • Lung Neoplasms (drug therapy, enzymology, genetics)
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors (administration & dosage, adverse effects)
  • Pyrazoles (administration & dosage, adverse effects)
  • Pyridines (administration & dosage, adverse effects)
  • Quality of Life
  • Receptor Protein-Tyrosine Kinases (antagonists & inhibitors, genetics, metabolism)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: